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A sputum 6 gene signature predicts future exacerbations of poorly controlled asthma.  1 
 2 
Author list: 3 
Michael Fricker, BSc PhD1, Peter G Gibson, MBBS FRACP1,2,14, Heather Powell, 4 
MMedSci1,2, Jodie L Simpson, BSc PhD1, Ian A Yang, MBBS PhD FRACP3,4, John W 5 
Upham, MBBS PhD3,5, Paul N Reynolds, MBBS MD PhD FRACP6,7,8, Sandra Hodge, 6 
PhD6,7,8, Alan L James MBBS MD FRACP9,10, Christine Jenkins, MBBS MD FRACP11,12, 7 
Matthew J Peters, MD FRACP12,13, Guy B Marks, MBBS PhD FRACP14,15, Melissa Baraket 8 
MBBS PhD FRACP16, Katherine J Baines, BSc PhD1 9 
 10 
Affiliations: 11 
1Priority Research Centre for Healthy Lungs, The University of Newcastle, Newcastle, NSW, 12 
Australia 13 
2Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW, 14 
Australia 15 
3Diamantina Institute, The University of Queensland, Brisbane, QLD, Australia 16 
4Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, QLD, Australia 17 
5Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, QLD, 18 
Australia 19 
6Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia 20 
7Lung Research Laboratory, Hanson Institute, Adelaide, SA, Australia 21 
8School of Medicine, University of Adelaide, Adelaide, SA, Australia 22 
9Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, 23 
Perth, WA, Australia 24 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
10School of Medicine and Pharmacology, The University of Western Australia, Perth, WA, 25 
Australia 26 
11Respiratory Trials, The George Institute for Global Health, Sydney, NSW, Australia 27 
12Department of Thoracic Medicine, Concord General Hospital, Sydney, NSW, Australia 28 
13Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia 29 
14Woolcock Institute of Medical Research, Sydney, NSW, Australia 30 
15South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, 31 
Australia 32 
16Respiratory Medicine Department and Ingham Institute Liverpool Hospital, University of 33 
New South Wales, Medicine Faculty, Sydney, NSW, Australia 34 
 35 
Corresponding author contact details:  36 
Michael Fricker 37 
Address: Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, Lot 38 
1 Kookaburra Circuit, New Lambton Heights, NSW, 2305, Australia.  39 
Phone: +61 2 404 20207 40 
Fax: +61 2 404 20046 41 
 42 
Email: michael.fricker@newcastle.edu.au 43 
 44 
Declaration of all funding sources: This study was funded by the National Health and 45 
Medical Research Council of Australia (NHMRC project identifiers 569246, 1058552 and 46 
1078579) and the John Hunter Hospital Charitable Trust. 47 
 48 
Conflict of interest statement: M.F. has received research and fellowship funding from the 49 
NHMRC, Thoracic Society of Australia and New Zealand and AstraZeneca, and declares no 50 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3
conflict of interest in relation to this paper. P.G.G. has received research and fellowship 51 
funding from the NHMRC, research funding from AstraZeneca, GlaxoSmithKline, and 52 
Novartis, and speaker fees from AstraZeneca, GlaxoSmithKline, and Novartis, unrelated to 53 
the current manuscript. H.P. declares no conflict of interest. J.L.S. declares no conflict of 54 
interest in relation to this paper. I.A.Y. declares no conflict of interest in relation to this 55 
paper. J.U. has received speaker fees and consultancy fees from AstraZeneca, 56 
GlaxoSmithKline, Novartis, Boehringer Ingelheim and Menarini, none of these were related 57 
to the current manuscript. P.N.R. has received speaker fees from Boehringer Ingelheim and 58 
Roche, none of these were related to the current manuscript. S.H.’s institution has grants with 59 
NHMRC; and she has received royalties from the book Lung Macrophages in Health and 60 
Disease. A.L.J. has received speaker fees from AstraZeneca, GlaxoSmithKline and Menarini, 61 
none of these were related to the current manuscript. C.J. has received personal payments for 62 
advisory board membership, speaker engagement and educational resource development 63 
from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Menarini. Her 64 
institution receives grants from GlaxoSmithKline and AstraZeneca. She has no conflict of 65 
interest in relation to this paper and received no payments in relation to the work undertaken. 66 
M.J.P. declares no conflict of interest in relation to this manuscript. G.M.’s institution has 67 
received research funding from AstraZeneca and GlaxoSmithKline and he has served an on 68 
an advisory board for AstraZeneca. He has no conflicts of interest in relation to this 69 
manuscript. M.B. declares no conflict of interest in relation to this paper. K.J.B. received 70 
research funding from the NHMRC CRE Severe Asthma for this work and a Lung 71 
Foundation Australia fellowship. K.J.B. and P.G.G. have a patent pending, “Biomarkers of 72 
asthma inflammatory phenotypes and response to therapy”, regarding use of the 6GS as a 73 
phenotyping tool in asthma.  74 
 75 
76 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 4
Abstract:  77 
• Background: Improved diagnostic tools for predicting future exacerbation frequency 78 
in asthma are required. A sputum gene expression signature of 6 biomarkers (6GS - 79 
including CLC, CPA3, DNASE1L3, ALPL, CXCR2, IL1B) predicts inflammatory and 80 
treatment response phenotypes in stable asthma. We recently demonstrated that 81 
azithromycin (AZM) add-on treatment in uncontrolled moderate-to-severe asthma 82 
significantly reduced asthma exacerbations (AMAZES clinical trial). 83 
• Objectives: To test whether the 6GS predicts future exacerbation and inflammatory 84 
phenotypes in a subpopulation of AMAZES. To test the impact of AZM therapy on 85 
6GS expression and prognostic capacity. 86 
• Methods: 142 patients (73 placebo-treated, 69 AZM-treated) had sputum stored for 87 
qPCR of 6GS markers at baseline and after 48 weeks of treatment. Logistic 88 
regression, ROC and AUC were performed on baseline measures, and in an 89 
exploratory analysis the predictive value of 6GS was compared with conventional 90 
biomarkers for exacerbation and inflammatory phenotypes.  91 
• Results: The 6GS significantly predicted all future exacerbation phenotypes tested. 92 
Calculated AUCs for 6GS were significantly higher than AUCs for peripheral blood 93 
eosinophil counts, sputum neutrophil counts and combined sputum eosinophils and 94 
neutrophil counts.  6GS AUCs were also were numerically, but not significantly, 95 
higher than FeNO and sputum eosinophil counts. AZM treatment neither altered the 96 
6GS expression nor the predictive capacity of the 6GS for future exacerbation 97 
phenotypes. The 6GS was a significant predictor of airway inflammatory phenotype 98 
in this population. 99 
• Conclusion: We demonstrate that a sputum gene signature can predict future 100 
exacerbation phenotypes of asthma, with greatest biomarker performance in 101 
identifying those who would experience frequent severe exacerbations. AZM therapy 102 
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did not modify 6GS expression or biomarker performance, suggesting the therapeutic 103 
action of AZM is independent of 6GS-related inflammatory pathways. 104 
 105 
Key Messages  106 
• Sputum gene signatures may offer a superior means to predict future exacerbations of 107 
asthma compared to conventional biomarkers. 108 
• Our data suggest a therapeutic mechanism of AZM which is independent of 109 
inflammatory factors associated with the 6GS (airway eosinophilia, neutrophilia, mast 110 
cells).  111 
 112 
Capsule Summary: 113 
In this AMAZES RCT sub-analysis, the sputum 6GS predicts exacerbation and airway 114 
inflammatory phenotype of uncontrolled, moderate-to-severe asthma. Azithromycin appears 115 
to exert a therapeutic effect independently of 6GS-related airway inflammatory factors. 116 
 117 
Key words: Asthma, sputum, biomarker, inflammation, exacerbation, macrolide, 118 
azithromycin, eosinophil, gene signature, clinical trial 119 
 120 
Abbreviations: 121 
6GS  6 gene signature 122 
ACQ  Asthma control questionnaire-6 123 
ALPL  Alkaline Phosphatase, liver/bone/kidney 124 
AUC  Area under curve 125 
AZM  Azithromycin 126 
CLC  Charcot-Leyden Crystal Galectin 127 
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CPA3  Carboxypeptidase 3 128 
CXCR2 C-X-C motif chemokine receptor 2 129 
DNASE1L3 Deoxyribonuclease 1 like 3 130 
EA  Eosinophilic asthma 131 
FENO  Fractional exhaled nitric oxide 132 
ICS  Inhaled corticosteroid 133 
IL1B  Interleukin-1β 134 
MGA  Mixed granulocytic asthma 135 
NA  Neutrophilic asthma 136 
NEA  Non-eosinophilic asthma 137 
NNA  Non-neutrophilic asthma 138 
NPGA  Non-paucigranulocytic asthma 139 
OCS  Oral corticosteroid 140 
PBE  Peripheral blood eosinophil 141 
PGA  Paucigranulocytic asthma 142 
RCT  Randomized controlled trial 143 
ROC  Receiver operating characteristic 144 
 145 
  146 
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Introduction 147 
 148 
Asthma is a chronic respiratory disease characterized by variable or reversible airflow 149 
obstruction, often featuring airway inflammation. Analysis of induced sputum, through 150 
quantification of relative abundance of eosinophils and neutrophils, allows classification of 151 
asthma into inflammatory phenotypes1-3. Airway inflammometry can help guide the choice of 152 
conventional and emerging treatments for asthma patients4, 5. Eosinophilic airway 153 
inflammation, in contrast to neutrophilic inflammation, is corticosteroid sensitive, and 154 
tailoring of inhaled corticosteroid (ICS) therapy guided by sputum eosinophil quantification 155 
showed greater benefit in clinical trials compared to conventional management6-8.  156 
 157 
Sputum induction, processing and analysis is technically demanding and therefore limited to 158 
specialist clinical research laboratories. Thus, recent research has centered on identification 159 
of biomarkers of airway inflammation which can be easily accessed and measured. Peripheral 160 
blood eosinophils (PBE) and fractional exhaled nitric oxide (FENO) have demonstrated some 161 
value as biomarkers for selection of patients responsive to novel biological therapies 162 
targeting type-2 inflammation4, but at best show modest correlation with airway 163 
inflammatory phenotype and have not proved accurate in predicting responsiveness to 164 
corticosteroids. Therefore improved biomarkers are needed. 165 
 166 
Recent transcriptomic and proteomic studies have extended the assessment of sputum 167 
inflammation9-12. We previously reported a sputum gene expression signature comprised of 6 168 
transcripts (CLC, CPA3, DNASE1L3, ALPL, CXCR2, IL1B) which distinguished airway 169 
inflammatory phenotypes of asthma with high specificity and sensitivity13. CLC, CPA3 and 170 
DNASE1L3 expression are increased in eosinophilic asthma. ALPL, CXCR2 and IL1B are 171 
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increased in neutrophilic asthma and mark innate inflammatory signaling pathways relating 172 
to TNFα, CXCL1 and IL-1β respectively. This 6 gene signature (6GS) also predicts 173 
responsiveness to inhaled13 and oral corticosteroids (OCS)14, which suppress CLC, CPA3 and 174 
DNASE1L3 expression. The development of sputum gene signatures may increase the 175 
feasibility of use of sputum-based measures in the clinic, as the sample processing (RNA 176 
extraction, cDNA synthesis, qPCR) can be automated, and the markers have high specificity.  177 
 178 
We recently published findings from a clinical trial (AMAZES) which demonstrated that 179 
treatment of moderate-to-severe, uncontrolled asthma with the macrolide AZM reduced 180 
exacerbation frequency and improved quality of life over a 48-week period15. In this study, 181 
none of the inflammatory or clinical features examined at baseline identified an AZM-182 
responsive subpopulation. The mechanism of action whereby AZM reduces asthma 183 
exacerbations remains unclear, and could be related to its anti-inflammatory, anti-bacterial or 184 
anti-viral properties.  185 
 186 
In the present study, we evaluate the ability of the sputum 6GS to predict asthma 187 
exacerbation frequency and to differentiate airway inflammatory phenotype in a 188 
subpopulation of the AMAZES trial. The effect of AZM treatment on 6GS expression and 189 
prognostic potential was tested. The prognostic potential of the 6GS was compared to sputum 190 
cell count, PBE and FENO.  We hypothesized that the 6GS would provide superior 191 
prediction of exacerbation and inflammatory phenotype compared to other biomarkers.  192 
  193 
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Methods 194 
The AMAZES study15 was a double-blind placebo-controlled trial where 420 adults with 195 
persistent symptomatic asthma despite current use of ICS and long-acting bronchodilator 196 
were randomized to receive AZM 500mg 3 times per week or identical placebo for 48 weeks 197 
(Online Repository). Induced sputum was collected prior to randomization and at 48 weeks. 198 
Asthma exacerbations were recorded as the primary study outcome15. The trial was approved 199 
by institutional ethics committees. All patients provided written informed consent. 200 
 201 
Clinical methods 202 
We performed the present analysis on a subset of AMAZES study participants15 who were 203 
included if sputum was available for differential cell count and qPCR analysis from both the 204 
baseline and 48-week visits. Sputum induction and analysis was performed using our 205 
previously described methods (see Online Repository). Inflammatory phenotypes were 206 
defined as follows: eosinophilic asthma (EA, sputum eosinophils ≥ 3%7); neutrophilic asthma 207 
(NA, sputum neutrophils ≥ 61%1); mixed granulocytic asthma (MGA, sputum neutrophils ≥ 208 
61% and eosinophils ≥ 3%); paucigranulocytic asthma (PGA, sputum neutrophils < 61% and 209 
eosinophils < 3%). In the AMAZES trial exacerbation occurrence and type (severe or 210 
moderate) were determined by structured interview. Decisions regarding treatment of trial 211 
participants during exacerbation were determined by the treating physicians, and were not 212 
part of the trial. Severe exacerbations were defined as a worsening of asthma symptoms 213 
requiring ≥3 days of systemic corticosteroid treatment ≥10mg/day, or an asthma-specific 214 
hospitalization or emergency department visit requiring systemic corticosteroids. Moderate 215 
exacerbations were defined as any temporary increase in ICS or antibiotics in conjunction 216 
with a deterioration in asthma symptoms or both (change in ACQ6 of at least 0.5 or increased 217 
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diary symptom score), or any increase in β2 agonist use for at least 2 days, or an emergency 218 
department visit not requiring systemic corticosteroids. 219 
 220 
Gene expression analysis 221 
Sputum gene expression of CLC, CPA3, DNASE1L3, ALPL, CXCR2, IL1B was quantified as 222 
previously described9 (see Online Repository). Statistical analysis of diagnostic ability was 223 
performed on the change in cycle threshold (∆Ct) between the target gene and housekeeping 224 
β-actin. For relative gene expression levels, data were log transformed (2-∆Ct). 225 
 226 
Statistical analysis 227 
The risk of being an exacerbator, as opposed to a non-exacerbator, was modelled by logistic 228 
regression (STATA 13, StataCorp, College Station, Texas, USA) using single (univariate) or 229 
a combination of markers (multiple logistic regression). Several alternative binary definitions 230 
of exacerbator status were used for the dependent variable according to both the frequency 231 
and the severity of exacerbations. These included one or more vs none (any exacerbations) 232 
and two or more vs one or none (frequent exacerbations), where exacerbations included all 233 
exacerbations (total moderate and severe) or were limited to severe exacerbations15. To 234 
examine the potential effect of AZM treatment on the relationship between 6GS and future 235 
exacerbation, each model was adjusted for AZM treatment and conducted with and without 236 
interaction terms for treatment and the individual gene expression. The models with and 237 
without the interaction terms were then compared using a log likelihood ratio test and, if non-238 
significant, p>0.05, the models with no interaction terms were used. 239 
For each exacerbator status outcome and predictor set, each member of the study population 240 
was assigned a predicted value for the 6GS which was generated by input of the 6 genes as 241 
individual variables in a multiple logistic model according to exacerbator status outcome. 242 
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Similarly, each member of the study population was assigned a predicted value for the other 243 
biomarkers tested by the logistic model adjusted for AZM treatment. 244 
Receiver Operating Characteristic (ROC) curves were generated of the 6GS and other 245 
biomarker predicted values by exacerbator (outcome) status for each exacerbation model. 246 
Area under the curve (AUC) was estimated for each model as an indicator of the predictive 247 
accuracy of that model.   248 
In an exploratory analysis, ROC curves for the 6GS were compared with traditional 249 
biomarker ROC curves including sputum eosinophil %, PBE and FENO. The predictive 250 
capacity of the 6GS (with and without adjustment for prior history of OCS use) and prior 251 
history of OCS use alone for severe exacerbations were also compared. Significance was 252 
accepted when p<0.05. 253 
Similar logistic or multiple logistic regression with ROC curve analysis was performed to test 254 
the ability of the 6GS, PBE and FENO to predict airway inflammatory phenotype at baseline.  255 
For analysis of qPCR data, Mann-Whitney was used for comparison between inflammatory 256 
subtypes and comparison at visit 10 between treatments. For comparison of baseline to visit 257 
10 data within each treatment group Wilcoxon paired test was performed.  258 
  259 
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Results 260 
Subject Characteristics 261 
Most patients were classified as GINA step 4 (85.9%) and 48.6% as having severe asthma 262 
(ERS/ATS guidelines)16 and all had persistent symptomatic (ACQ6 ≥ 0.75) asthma despite 263 
ongoing treatment15. Major clinical and inflammatory characteristics were similar between 264 
participants randomized to the placebo and AZM arms of the trial, including age, gender, 265 
asthma control, asthma severity, spirometry and systemic and airway inflammatory measures 266 
(table I). Of note, the primary outcome of reduced exacerbations in AZM-treated patients 267 
previously reported in the whole AMAZES cohort was recapitulated in this subpopulation 268 
(table I).  269 
 270 
The 6GS is significantly associated with future exacerbations, independently of AZM 271 
treatment status 272 
We first examined the relationship between 6GS measurement at baseline and exacerbations 273 
subsequently recorded during the 48-week AMAZES trial (moderate and severe or severe 274 
only). There was no significant interaction between AZM treatment and the relationship 275 
between 6GS and future exacerbations and no significant difference between the models with 276 
or without interaction terms. A significant association was observed between the combined 277 
6GS components and future moderate and severe exacerbations (model P = 0.036) and future 278 
frequent severe exacerbations (model P = 0.022).  279 
 280 
The 6GS outperforms traditional biomarkers as a prognostic test for future 281 
exacerbation phenotypes 282 
In a series of exploratory analyses, we performed logistic regression with ROC analysis using 283 
the 6GS, sputum eosinophils and/or neutrophils, PBE and FENO quantified at baseline to 284 
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evaluate their relative prognostic value for various exacerbation phenotypes based on 285 
exacerbations recorded during the trial period. As there was no interaction between AZM 286 
treatment and the association of 6GS with future exacerbations, we combined placebo and 287 
AZM-treated patients in our initial analysis. 288 
 289 
Sputum eosinophils, sputum neutrophils, PBE and FENO did not provide statistically 290 
significant discriminatory capacity for those patients that experienced at least one severe 291 
exacerbation (exacerbators) during the trial from those that experienced none (non-292 
exacerbators) (figure 1A and table II). In contrast the sputum 6GS provided modest but 293 
significant prediction of severe exacerbators vs non-exacerbators (AUC = 68.1%, P < 0.0001) 294 
(table II and supplemental table E1).  295 
 296 
Sputum eosinophils, eosinophils and neutrophils combined and the 6GS provided significant 297 
discriminatory capacity of patients who experienced frequent (≥ 2) vs infrequent (< 2) severe 298 
exacerbations (6GS AUC = 76.1%, P < 0.0001; sputum eosinophil AUC = 70.3%, P = 0.002; 299 
sputum eosinophils and neutrophils AUC = 68.4%, P = 0.012) (figure 1B and table II). In the 300 
subset of patients where FENO was measured, both 6GS and FENO provided significant 301 
prognostic capacity (6GS AUC = 83.7%, P < 0.0001; FENO AUC = 75.6%, P < 0.0001). Of 302 
all biomarkers examined, the sputum 6GS gave the highest AUC values and significantly 303 
outperformed sputum neutrophils, eosinophils and neutrophils combined and PBE in 304 
predicting the frequent severe exacerbation phenotype (table II and supplemental table E2).  305 
 306 
In the AMAZES study moderate exacerbations were also quantified15. We performed logistic 307 
regression analysis comparing exacerbator vs non-exacerbator and frequent vs infrequent 308 
exacerbator phenotypes for total (sum of moderate and severe) exacerbations. The 6GS and 309 
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sputum eosinophils and/or neutrophils significantly predicted exacerbators vs non-310 
exacerbators (total) (6GS AUC = 69.6%, P < 0.0001; eosinophils AUC = 63%, P = 0.008; 311 
neutrophils AUC = 63.3%, P = 0.005; eosinophils and neutrophils AUC = 64.2%, P = 0.003) 312 
(figure 1C, table II, supplemental table E3). In this analysis 6GS statistically outperformed 313 
sputum neutrophils and PBE. The 6GS and sputum eosinophils and/or neutrophils 314 
significantly discriminated frequent (≥ 2) total exacerbators from infrequent exacerbators 315 
(6GS AUC = 66.4%, P = 0.001; eosinophils AUC = 60.6%, P = 0.034; neutrophils AUC = 316 
60.8%, P = 0.029; eosinophils and neutrophils AUC = 62.1%, P = 0.016) (figure 1D, table II, 317 
supplemental table E4), and the 6GS significantly outperformed PBE. 318 
 319 
History of OCS use for the 12-month period prior to the study baseline visit was recorded. 320 
Prior OCS history alone could significantly predict the future severe exacerbation frequency 321 
with a similar AUC to the 6GS (Prior OCS use AUC = 76.5%, p < 0.0001). When 6GS was 322 
evaluated and the data adjusted for prior OCS history, the highest AUC for predicting the 323 
severe exacerbation phenotype was achieved (6GS adjusted for prior OCS use AUC = 79.8%, 324 
p < 0.0001) (figure 1E).  325 
 326 
AZM treatment does not alter 6GS expression nor prediction of future exacerbation 327 
status 328 
We evaluated the effect of 48 weeks AZM treatment on 6GS transcript expression. At visit 329 
10 (48 weeks of treatment), there was no significant difference in 6GS expression between 330 
placebo and AZM treatment groups (figure 2, A-F). CXCR2 mRNA was significantly 331 
increased at visit 10 vs baseline visits in both placebo and AZM-treated patients (figure 2, E). 332 
In a further exploratory sub-analysis, we examined biomarker performance for the various 333 
exacerbator phenotypes, analyzing placebo- and AZM-treated groups separately. Of note, 334 
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6GS retained statistically significant predictive capacity for all exacerbation phenotypes 335 
examined in both placebo and AZM-treated groups, with the exception of prediction of 336 
frequent exacerbators (total) in the AZM-treated patients (AUC = 62.7%, P = 0.097) (figure 337 
2, G-J, supplemental tables E5-9). Other biomarkers did not provide significant predictive 338 
capacity for any exacerbator phenotype in either placebo or AZM-treated groups, with the 339 
exception of sputum eosinophils for predicting frequent severe exacerbators in the placebo 340 
group (AUC = 70.1%, P = 0.004) (supplemental table E5).  341 
 342 
6GS predicts airway inflammatory phenotype in a population with uncontrolled 343 
moderate-to-severe asthma 344 
Airway expression of CLC, CPA3 and DNASE1L3 were significantly elevated in eosinophilic 345 
(EA; ≥ 3% sputum eosinophils) vs non-eosinophilic (NEA; < 3% sputum eosinophils) 346 
asthma, whilst IL1B was lower in EA (figure 3A). CXCR2 and ALPL expression did not 347 
differ between EA and NEA. IL1B, CXCR2 and ALPL were significantly elevated in 348 
neutrophilic (NA) vs non-neutrophilic (NNA) asthma, whilst expression of CLC, CPA3 and 349 
DNASE1L3 showed no significant differences between these groups (figure 3B).  350 
 351 
We tested whether the 6GS measured at baseline could predict airway inflammatory 352 
phenotype, using multiple logistic regression and ROC curve analysis. In all analyses, the 353 
sputum 6GS discriminated airway inflammatory phenotypes to a statistically significant 354 
extent (EA vs NEA: AUC = 76.8%, P < 0.0001; EA vs NA: AUC = 92.9%, P < 0.0001; EA 355 
vs PGA: AUC = 76.4%, P < 0.0001; NA vs NNA: AUC = 89.5%, P < 0.0001; NA vs PGA: 356 
AUC = 88.0%, P < 0.0001; PGA vs NPGA: AUC = 74.0%, P < 0.0001) (table III). We also 357 
examined two established biomarkers of type 2/eosinophilic inflammation in asthma, PBE 358 
and FENO, and compared their performance with the 6GS in distinguishing sputum 359 
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inflammatory phenotypes. Both PBE and FENO discriminated EA vs NEA, EA vs NA and 360 
EA vs PGA to a statistically significant extent (supplemental table E10). However, the 6GS 361 
significantly outperformed PBE (figure 3C) and FENO (figure 3D) as a diagnostic test for 362 
predicting EA vs NA. 363 
  364 
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Discussion 365 
In this study, we demonstrate that the sputum 6GS can predict future exacerbation phenotype 366 
in a cohort of patients with uncontrolled, moderate-to-severe asthma. Furthermore we find 367 
that AZM did not alter 6GS expression relative to placebo, and that the 6GS retains its 368 
prognostic utility even in patients whom were treated with AZM add-on therapy, which 369 
reduced overall rate of exacerbations compared to the placebo treatment. The sputum 6GS 370 
had statistically better predictive capacity for future frequent severe exacerbations than PBE, 371 
sputum neutrophils and combined sputum eosinophil and neutrophil count. Numerically, but 372 
not statistically, superior AUC values were also observed for 6GS compared to sputum 373 
eosinophils and FENO in the prediction of future exacerbation phenotypes. 374 
 375 
Sputum 6GS predicts future exacerbations more effectively than conventional 376 
biomarkers 377 
Development of biomarkers that can identify asthma patients most likely to experience 378 
frequent exacerbations would be useful to target treatment for this at-risk population. At 379 
present the best indicator of future exacerbation probability is past exacerbation frequency17, 380 
18
, however this does not assist in selecting treatment options. Patients with elevated 381 
eosinophilic or type 2 inflammatory biomarkers including sputum eosinophils, PBE and 382 
FENO experience more frequent severe exacerbations19-22. In the present study, using ROC 383 
analysis to evaluate biomarker potential, we demonstrate that the sputum 6GS can 384 
discriminate future exacerbators from non-exacerbators and frequent from non-frequent 385 
exacerbators, when either severe exacerbations or total exacerbations were modeled. In all 386 
but one ROC analyses performed, the sputum 6GS generated higher AUC values than 387 
conventional biomarkers. Performance of conventional biomarkers was inconsistent, and in 388 
exploratory comparative analysis the 6GS frequently statistically outperformed sputum 389 
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neutrophils and PBE. The sputum 6GS matched past courses of OCS as a predictor of 390 
frequent severe exacerbations over the following 48 weeks. The ability of the 6GS to identify 391 
patients who would go on to experience frequent severe exacerbations was further enhanced 392 
when we adjusted for prior OCS courses, giving an AUC value of 80%, which corresponds to 393 
a good performance as a prognostic tool. To our knowledge this is the best such score 394 
reported for the identification of patients who would go on to experience frequent severe 395 
exacerbations over the following year. Of note, the 6GS was initially developed as an 396 
inflammatory phenotyping tool13, thus whilst these results demonstrate the promise of sputum 397 
gene signatures to identify patients most at risk of exacerbation, improved biomarker 398 
performance may be achieved in the future through further gene signature optimization. 399 
 400 
Why might the sputum 6GS outperform conventional inflammatory biomarkers as a 401 
prognostic tool in this instance? One possibility is that the 6GS reports on multiple 402 
inflammatory variables that impact on asthma exacerbation frequency, as opposed to a single 403 
variable in isolation. For example, although sputum neutrophil count in this study was a poor 404 
prognostic marker for future exacerbation status, high sputum neutrophil count has been 405 
linked to more severe forms of asthma in cluster analysis, associated with higher healthcare 406 
burden and hospitalization, particularly when accompanied by elevated sputum eosinophils23. 407 
Combinatorial use of biomarkers reporting on distinct disease endotypes or markers could 408 
improve prognostic potential. In agreement with this hypothesis, combinatorial use of type 2-409 
related biomarkers FENO, PBE and serum periostin improves prediction of exacerbation risk 410 
when compared to each variable in isolation24. The individual gene markers within the 6GS 411 
combine information about the eosinophilic and neutrophilic inflammatory status of the 412 
airways. However, in our study combinatorial use of sputum eosinophil and neutrophil 413 
proportions provided little or no improvement compared to each variable in isolation.  414 
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The 6GS may provide information relating to airway inflammatory status beyond merely 415 
relating to the cellular composition of the sputum sample. We have shown previously that 416 
airway IL1B expression is elevated in frequent exacerbators in both COPD and asthma25, 26. It 417 
is also possible that the 6GS improves on sputum eosinophil and neutrophil count in 418 
prognostic tests because it reflects cellular inflammation or processes not reported in 419 
conventional sputum analysis. CPA3 encodes a carboxypeptidase expressed exclusively in 420 
mast cells in humans11, 27, 28. Our and others’ sputum transcriptomic analyses identified a 421 
number of mast cell-related genes that were upregulated in eosinophilic asthma9, 10, 11. A 422 
recent study reported flow cytometry-based quantification of sputum mast cells and 423 
demonstrated positive correlation with sputum eosinophil count29. Of the 6GS genes, CPA3 424 
and CLC were the most effective at predicting the frequent severe exacerbator phenotype 425 
(supplemental table E2). CLC may be expressed in both eosinophils and basophils, which are 426 
correlated in sputum samples29, 30. Thus, the potential of the sputum 6GS to provide 427 
information relating to mast cell and basophil-related inflammation in addition to eosinophils 428 
and neutrophils may explain its superior performance as a predictor of exacerbation 429 
phenotype.  430 
 431 
AZM add-on treatment does not modify sputum 6GS expression or prognostic capacity 432 
despite significantly reducing exacerbation rate.  433 
In the primary analysis of the AMAZES trial, we demonstrated that AZM add-on therapy in 434 
uncontrolled moderate-to-severe asthma reduced asthma exacerbations by approximately 435 
40% and improved asthma related quality of life scores15. In our initial analysis we were 436 
unable to identify asthma related variables (clinical, inflammatory or microbiological) that 437 
predicted AZM response15. AZM treatment did not alter most systemic and airway 438 
inflammatory variables measured, with the exception being a significant reduction in the 439 
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absolute number (but not proportion) of sputum eosinophils. Macrolides including AZM 440 
exert anti-bacterial, anti-viral and anti-inflammatory effects, all of which could explain the 441 
reduction in asthma exacerbations observed31, 32. Our present analysis concludes that AZM 442 
add-on treatment did not significantly affect expression of the sputum 6GS genes. However, 443 
the lack of effect of AZM on sputum 6GS expression is in agreement with the prior analysis 444 
that AZM did not affect sputum or systemic inflammatory biomarkers. Consistent with this, 445 
we also found that the sputum 6GS could significantly predict future exacerbation 446 
phenotypes in most analyses conducted in AZM-treated patients, despite the fact that 447 
exacerbation rate was significantly reduced by AZM treatment. The implications of our 448 
findings are that the mechanism of action whereby AZM treatment reduces exacerbation rate 449 
is discrete from the inflammatory pathways reflected by the sputum 6GS, including sputum 450 
eosinophils, neutrophils and mast cells.  451 
 452 
Sputum 6GS is a useful tool for discriminating asthma inflammatory phenotypes in 453 
moderate-to-severe asthma 454 
The findings of the present study further consolidate and broaden the potential use of 6GS as 455 
an inflammatory phenotyping tool in asthma. Here we demonstrate for the first time that the 456 
6GS is effective as a diagnostic predictor of inflammatory phenotype in a cohort of patients 457 
with uncontrolled moderate-to-severe asthma. These results add to our prior work assessing 458 
the utility of the sputum 6GS in stable, mild-to-moderate asthma13 and as a predictor of 459 
positive response to ICS and OCS13, 14. Thus, we establish that the sputum 6GS provides 460 
excellent airway inflammatory phenotyping capacity across all asthma severities. 461 
This study does have limitations. This was a secondary analysis of our previously published 462 
AMAZES RCT15. Our comparative analysis of biomarkers was exploratory, and further 463 
validation of the 6GS as a prognostic tool for future exacerbation phenotypes would require 464 
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prospective recruitment of patients in a study designed to address this specific question. 465 
Notably, due to the requirement of sufficient sputum sample to allow RNA isolation and 466 
qPCR analysis for our present study, only those patients that produced sufficient sputum were 467 
included, and this could be a source of biological bias. In this sub-population of the 468 
AMAZES RCT, FENO data was not available for all patients, and thus our analysis of FENO 469 
as a prognostic tool, and comparisons of its performance with the sputum 6GS, are likely 470 
underpowered and thus not definitive. We cannot exclude that integration of gene signatures 471 
with cell counts could provide superior performance by better reflecting the activation status 472 
of key immune pathways, and this should be explored in future studies. 473 
 474 
In conclusion, the sputum 6GS can predict future exacerbation phenotype in moderate-to-475 
severe asthma, demonstrating the prognostic potential of gene signatures. We also conclude 476 
that AZM exerts a therapeutic mechanism independent of the inflammatory factors reported 477 
by the sputum 6GS, and that the 6GS may still retain use in identifying a subset of patients 478 
who may experience frequent severe exacerbations despite AZM therapy. 479 
  480 
  481 
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Tables  489 
Table I. Subject Characteristics 490 
 491 
 All 
 
Placebo Group 
 
Azithromycin Group 
 
N 142 73 69 
Age
Ω
 60.62 (49.79, 69.14) 60.01 (48.78, 67.80) 62.21 (53.21, 69.19) 
Sex M/F 65/77 33/40 32/37 
Atopy
¥
 110 /139 (79.1%) 57/70 (81.4%) 53/69 (76.8%) 
Ex-smoker
¥
 50 (35.2%) 26 (35.6%) 24 (34.8%) 
Pack years
Ω
 9.15 (1.30, 24.0) 9.2 (1.4, 25.0) 9.15 (1.3, 22.0) 
ACQ score
Ω
 1.58 (1.0, 2.17) 1.67 (1.17, 2.33) 1.33 (1.0, 2.17) 
GINA step 4
¥
 120 (84.5%) 61 (83.6%) 59 (85.5%) 
Severe asthma
¥
 69 (48.6%) 34 (46.6%) 35 (50.7%) 
Pre-b2 FEV1% 
Ψ
 73.85 (18.84) 73.23 (18.93) 74.52 (18.85) 
Pre-b2 FVC%
 Ψ
 84.07 (14.62 ) 82.70 (14.57) 85.55 (14.64) 
Pre-b2 FEV1/FVC%
 Ψ
 67.73 (11.19) 68.15 (10.92) 67.28 (11.54) 
ICS dose (BDP mcg/day)
 Ω
 1000 (800, 2000) 1000 (800, 2000) 1280 (800, 2000) 
FENO ppb
Ω
 25.80 (15.58, 47.45 )  
(n=68) 
31.65 (18.30, 53.0) 
(n=34) 
21.03 (14.30, 34.70) 
(n=34) 
Blood eosinophils (x 10
9
/L)
 Ω
 0.29 (0.2, 0.4) 0.3 (0.2, 0.4) 0.2 (0.12, 0.4) 
    
Sputum cell counts    
Sputum cell viability
Ω
 72.1 (55.4, 84.0) 78.0 (61.0, 86.1) 68.2 (53.3, 82.7) 
Total cell count (x 10
6
/ml)
 Ω
 4.55 (2.61, 7.56) 
(n=139) 
4.86 (2.70, 9.27) 
(n=73) 
4.23 (2.25, 6.75) 
(n=66) 
Neutrophils %
 Ω
 32.5 (14.0, 54.0) 33.5 (18.0, 55.0) 31.75 (12.50, 52.75) 
Eosinophils %
 Ω
 1.75 (0.50, 9.50) 2.0 (0.50, 6.25) 1.63 (0.25, 11.50) 
Macrophages %
 Ω
 50.50 (31.60, 69.0) 51.0 (31.75, 68.75) 45.63 (31.60, 69.0) 
Lymphocytes %
 Ω
 0.75 (0.25, 1.75) 0.75 (0.25, 1.50) 0.75 (0.25, 2.0) 
Columnar epithelial %
 Ω
 2.50 (1.0, 5.75) 2.50 (0.75, 4.75) 2.38 (1.25, 6.50) 
C2R stained eosinophils %
 Ω
 2.25 (0.50, 9.50) 2.50 (0.75, 9.25) 2.0 (0.50, 10.0) 
    
Sputum phenotype    
Eosinophilic
¥
 58 (41.7%) 32 (43.8%) 26 (39.4%) 
Neutrophilic
¥
 21 (15.1%)  13(17.8%) 8 (12.1%) 
Paucigranulocytic
¥
 55 (39.6%) 24 (32.9%) 31 (47.0%) 
Mixed
¥
 5 (3.6%) 4 (5.5%) 1 (1.5%) 
    
Exacerbations/person-year 
during AMAZES trial 
   
Total
 
 1.61  2.11  1.07 
∞
 
Severe
 
 0.77  1.04  0.48 
∞
 
Moderate
 
 0.84  1.07  0.59 
∞
 
Ω
Median (q1,q3); 
¥
(n(%); 
Ψ
Mean (SD); 
∞
Negative binomial regression p<0.03. 492 
493 
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Table II. AUC for each predictive marker by study population, exacerbation severity 494 
and exacerbation frequency status.  495 
  6GS Sputum 
eosinophils 
Sputum 
neutrophils 
Sputum 
Eosinophils 
& 
Neutrophils 
PBE 6GS  
(FENO)
 Ω
 
FENO 
  N=139 N=139 N=139 N=139 N=139 N=67 N=67 
T
o
ta
l e
xa
ce
rb
a
ti
o
n
s 
 
≥ 
1
 o
r 
0
 
AUC=0.696 
P<0.0001 
 
AUC=0.630 
P=0.008 
 
AUC=0.633* 
P=0.005 
 
AUC=0.642 
P=0.003 
 
AUC=0.596* 
P=0.058 
 
 
AUC=0.691 
P=0.004 
 
AUC=0.635 
P=0.056 
 
≥ 
2
 o
r 
0
-1
 AUC=0.664 
P=0.001 
 
AUC=0.606 
P=0.034 
 
AUC=0.608 
P=0.029 
 
 
AUC=0.621 
P=0.016 
AUC=0.566* 
P=0.181 
 
AUC=0.647 
P=0.029 
 
AUC=0.670 
P=0.010 
 
S
e
v
e
re
 e
xa
ce
rb
a
ti
o
n
s 
 
≥ 
1
 o
r 
0
 AUC=0.681 
P<0.0001 
 
AUC=0.579 
P=0.126 
 
 
AUC=0.549* 
P=0.348 
 
AUC=0.588 
P=0.083 
AUC=0.503
¥
 
P=0.957 
 
AUC=0.736 
P<0.0001 
 
AUC=0.618 
P=0.094 
 
≥ 
2
 o
r 
0
-1
 AUC=0.761 
P<0.0001 
 
AUC=0.703 
P=0.002 
 
AUC=0.631
¥
 
P=0.054 
 
AUC=0.684* 
P=0.012 
AUC=0.567
¥
 
P=0.281 
 
AUC=0.837 
P<0.0001 
 
AUC=0.756 
P<0.0001 
 
Ω
values calculated in subpopulation where FENO measurement was made *p<0.05 vs 6GS; 
¥
p<0.01 vs 6GS; 496 
∏
p<0.05 vs 6GS (FENO subpopulation); 
§
p<0.01 vs 6GS (FENO subpopulation) 497 
  498 
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Table III. Analysis of diagnostic value of the sputum 6GS for asthma airway 499 
inflammatory phenotype  500 
 501 
 Marker * Logistic Regression 
Constant Coefficient Model P 
value 
AUC 
(95%CI) 
EA vs NEA 
N=139 
ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
3.016208 0.1233148 
-0.0929966 
-0.3150406 
0.0323884 
-0.0486184 
0.1429728 
<0.0001 0.7684 
(0.6898, 
0.8469) 
P<0.0001 
EA vs NA 
N=79 
ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
3.645667 1.529648 
0.0586264 
-0.0971249 
-0.298909 
-0.9454183 
0.5770762 
<0.0001 0.9294 
(0.8637, 
0.9951) 
P<0.0001 
EA vs PGA 
N=118 
ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
4.249046 0.0063321 
-0.1013124 
-0.3867286 
-0.0325417 
0.0516468 
0.0999352 
0.0002 0.7636 
(0.6775, 
0.8498) 
P<0.0001 
NA vs NNA 
N=139 
ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
-2.034031 -0.8416046 
-0.2829233 
0.0170649 
-0.1026321 
0.766542 
-0.3135194 
<0.0001 0.8948 
(0.8294, 
0.9603) 
P<0.0001 
NA vs PGA 
N=81 
ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
1.820331 -0.5331606 
-0.4059778 
-0.0610565 
-0.2789399 
0.565322 
-0.2033842 
<0.0001 0.8804 
(0.8055, 
0.9553) 
P<0.0001 
PGA vs 
Granulocytic 
N=139 
ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
-4.316154 0.0509944 
0.1325146 
0.2796407 
0.1651778 
-0.1245273 
-0.0157521 
0.0004 0.7396 
(0.6561, 
0.5232) 
P<0.0001 
*Markers are normalized to beta-actin mRNA expression (∆CT)  502 
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Figures 503 
 504 
Figure 1. ROC analysis of diagnostic performance of 6GS, sputum eosinophils and/or 505 
neutrophils and PBE for predicting asthma exacerbation phenotypes. (double column, 506 
color) 507 
 508 
Figure 2. AZM treatment does not alter sputum 6GS expression or prognostic capacity 509 
compared to placebo. (double column) 510 
 511 
 512 
Figure 3. Sputum 6 gene signature expression in eosinophilic and neutrophilic subtypes 513 
of asthma and prediction of airway inflammatory phenotype. (double column, color) 514 
 515 
  516 
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Figure legends 608 
 609 
Figure 1. ROC analysis of diagnostic performance of 6GS, sputum eosinophils and/or 610 
neutrophils and PBE for predicting asthma exacerbation phenotypes. ROC curve 611 
comparison performed in both placebo- and AZM-treated patients (combined) enrolled in the 612 
AMAZES trial. Biomarkers examined: the sputum 6GS (black line), combined sputum 613 
eosinophils and neutrophils (pink line), sputum eosinophils (blue line), sputum neutrophils 614 
(red line) and PBE (green line). Comparisons shown are non-exacerbator vs exacerbator 615 
(severe exacerbations only) (A), infrequent exacerbator vs frequent exacerbator (severe 616 
exacerbations only) (B), non-exacerbator vs exacerbator (sum moderate and severe 617 
exacerbations) (C) and infrequent exacerbator vs frequent exacerbator (sum moderate and 618 
severe exacerbations) (D). ROC analysis was also performed to compare prognostic capacity 619 
of sputum 6GS, OCS courses (prior 12 months) and 6GS adjusted for prior OCS courses to 620 
identify frequent vs non-frequent severe exacerbators (E). (* = P < 0.05, ** = P < 0.01).  621 
 622 
Figure 2. AZM treatment does not alter sputum 6GS expression or prognostic capacity 623 
compared to placebo. qPCR was performed on cDNA generated from raw sputum samples 624 
collected during screening visits (visit 1/2) and a visit at end of the treatment period (week 625 
48, visit 10) for the AMAZES trial. CLC (A), CPA3 (B), DNASE1L3 (C), IL1B (D), CXCR2 626 
(E) and ALPL (F) data are reported as relative abundance normalized to expression of the 627 
housekeeping gene B-ACTIN (** = P < 0.01, *** = P < 0.001, Mann-Whitney). ROC curve 628 
comparison for the sputum 6GS in placebo arm (black line) compared with sputum 6GS in 629 
AZM arm (grey line). Comparisons shown are non-exacerbator vs exacerbator (severe 630 
exacerbations only) (G), infrequent exacerbator vs frequent exacerbator (severe 631 
exacerbations only) (H), non-exacerbator vs exacerbator (sum moderate and severe 632 
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exacerbations) (I) and infrequent exacerbator vs frequent exacerbator (sum moderate and 633 
severe exacerbations) (J).  634 
 635 
Figure 3. Sputum 6 gene signature expression in eosinophilic and neutrophilic subtypes 636 
of asthma and prediction of airway inflammatory phenotype. qPCR was performed on 637 
cDNA generated from raw sputum samples collected during screening visits for the 638 
AMAZES trial. CLC, CPA3, DNASE1L3, CXCR2, IL1B and ALPL data are reported as 639 
relative abundance normalized to expression of the housekeeping gene B-ACTIN. A) patients 640 
are separated into non-eosinophilic asthma (sputum eosinophils < 3%) and eosinophilic 641 
asthma (≥ 3%) groups. B) patients are separated into non-neutrophilic asthma (sputum 642 
neutrophils < 61%) and neutrophilic asthma (≥ 61%) groups. Data are expressed as median 643 
value with interquartile range. (* = P < 0.05, ** = P < 0.01, *** = P < 0.001, Mann-644 
Whitney). ROC curve comparison for the sputum 6GS (black line) compared with PBE 645 
(green line, panel C) and compared with FENO (pink line, panel D) (patient subgroup where 646 
FENO data was available). 6GS was better at distinguishing the EA from NA phenotypes 647 
than PBE or FENO (* = P < 0.05, ** = P < 0.01).  648 
 649 
 650 
 651 
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A sputum 6 gene signature predicts future exacerbations of poorly controlled asthma.  1 
Author list: 2 
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Matthew J Peters, MD FRACP12,13, Guy B Marks, MBBS PhD FRACP14,15, Melissa Baraket 7 
MBBS PhD FRACP16, Katherine J Baines, BSc PhD1 8 
ONLINE REPOSITORY 9 
SUPPLEMENTAL METHODS 10 
Trial Design 11 
The AMAZES trial was a multicentre, randomized, double-blind, placebo controlled parallel 12 
group trial that was designed to evaluate the efficacy and safety of oral azithromycin 500mg, 13 
three times weekly for 48 weeks, as add-on therapy in adults with persistent symptomatic 14 
asthma despite maintenance controller therapy with ICS/LABD.  420 patients were allocated 15 
to azithromycin or identical-looking placebo in a 1:1 ratio centrally using concealed random 16 
allocation from a computer-generated random numbers table with permuted blocks of 4 or 6 17 
and stratification for centre and past smoking. 18 
Trial Oversight 19 
A national steering committee of investigators designed the trial and was responsible for its 20 
conduct, analysis, interpretation, and reporting. Stenlake Compounding Pharmacy (Bondi 21 
Junction, NSW, Australia) prepared the study drug and matching placebo. The trial was 22 
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funded by the Australian Government’s National Health and Medical Research Council and 23 
there was no commercial input into any aspect of the trial. The trial was registered (ANZCTR 24 
No 12609000197235) and approved by institutional ethics committees. All patients provided 25 
written informed consent. 26 
Patients 27 
Patients were eligible if they had asthma defined as a compatible history and objective 28 
evidence of variable airflow obstruction from bronchodilator response (n=307,74.5%), airway 29 
hyperresponsiveness (n=129,56%) 1, 2, or increased peak flow variability (n=73, 44.7%); were 30 
currently symptomatic with at least partial loss of asthma control (asthma control score 31 
(ACQ6)>0.74) 3 despite treatment with maintenance ICS/LABD; were clinically stable with 32 
no recent exacerbation, infection or change in maintenance medication for at least 4 weeks 33 
prior to study entry; and were non-smokers (exhaled carbon monoxide < 10ppm). Exsmokers 34 
with a >10pack year smoking history underwent gas transfer testing and were excluded if 35 
their carbon monoxide gas transfer coefficient was <65% predicted. 36 
Procedures 37 
After a screening visit patients entered a 2 week run-in period.  Those with optimised asthma 38 
treatment, adherence to >80% of doses and who remained stable with change in ACQ6 of 39 
<0.5 were randomized. Patients were treated for 48 weeks and attended the clinic for 40 
assessment at weeks 6,12,24,36,48,52. Study visits assessed symptoms, medication use, 41 
asthma exacerbations, adherence, adverse events, and spirometry. Telephone assessments 42 
were conducted at weeks 18, 30, and 42. Induced sputum4  was performed before 43 
randomization and at the end of treatment visit (week 48). Adherence was assessed by tablet 44 
count returns at each visit. For safety monitoring, we assessed liver function tests and an 45 
electrocardiogram at screening, after 6 weeks of treatment, and at the end of treatment. QTc 46 
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prolongation >480mSec resulted in withdrawal from the trial.  Microbiological assessments 47 
involved sputum culture for recognised pulmonary pathogens (5 sites), and throat swab and 48 
nose swabs (2 sites) at randomisation and end of treatment. 49 
Outcomes 50 
Our primary outcome was the rate of severe asthma exacerbations over 48 weeks5, 6. Severe 51 
exacerbations were worsening of asthma symptoms requiring ≥3 days of systemic 52 
corticosteroid treatment ≥10mg/day, or an asthma-specific hospitalization or emergency 53 
department visit requiring systemic corticosteroids. Exacerbations were captured at all visits 54 
using structured interviewing. Secondary efficacy variables were ACQ6, asthma-related 55 
quality of life (AQLQ7, lung function, and induced sputum cell counts.  56 
Sputum induction and analysis 57 
Airflow limitation was assessed using spirometry (Medgraphics, CPFS/DTM usb Spirometer, 58 
BreezeSuite v7.1, Saint Paul, USA). Sputum induction with hypertonic saline (4.5%) was 59 
performed in participants whose FEV1 was ≥1L using our previously described methods8. In 60 
those with FEV1 <1L, 0.9% saline was used. For gene expression, Buffer RLT (Qiagen, 61 
Hilden, Germany) was immediately added to 100 µL of selected sputum and stored at -80°C 62 
until RNA extraction. For inflammatory cell counts, selected sputum was dispersed using 63 
dithiothreitol, and total cell count and viability were performed. Cytospins were prepared, 64 
stained (May-Grunwald–Giemsa) and a differential cell count obtained from 400 non-65 
squamous cells. 66 
Gene expression analysis 67 
Sputum gene expression of CLC, CPA3, DNASE1L3, ALPL, CXCR2, IL1B was performed as 68 
previously described9 (see Online Repository). Briefly, sputum RNA was extracted using the 69 
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Qiagen RNeasy Mini Kit, quantified, reverse-transcribed to cDNA and used to detect gene 70 
expression using standard Taqman real-time qPCR methods (Applied Biosystems, Foster 71 
City, USA). Statistical analysis of diagnostic ability was performed on the change in cycle 72 
threshold (∆Ct) between the target gene and housekeeping β-actin. For relative gene 73 
expression levels, data were log transformed (2-∆Ct). 74 
  75 
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SUPPLEMENTAL RESULTS 76 
Supplemental Table E1. Analysis of prognostic value of the sputum 6GS for discriminating 77 
patients who experience none or some severe asthma exacerbations in the following 48 weeks  78 
 79 
  Marker * Logistic Regression 
 Constant Coefficient Model P 
value 
AUC  
N
=
1
4
2
 (
5
1
/1
4
2
, 
3
5
.9
%
 s
e
v
e
re
 e
x
a
ce
rb
a
to
rs
) 
Individual      
 ALPL 0.6821072 -0.1729284 0.0888 0.6132 
P=0.026 
 CLC 1.157094 -0.1759621 0.0179 0.6391 
P=0.003 
 CPA3 1.238786 -0.1685756 0.0379 0.6152 
P=0.016 
 CXCR2 -0.3657592 -0.0095939 0.6181 0.5490 
P=0.354 
 DNASE1L3 1.33276 -0.1507057   0.1685 0.5893 
P= 0.074 
 IL1B -0.1105435 -0.1005466 0.3594 0.5652 
P=0.204 
Combination      
6GS ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
1.107549 -0.2649145 
-0.1413991 
-0.1169522 
0.2247225 
0.1312494 
-0.049104 
0.0522 0.6889 
P<0.0001 
*Markers are normalized to beta-actin mRNA expression (∆CT)  80 
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Supplemental Table E2. Analysis of diagnostic value of the sputum 6GS for discriminating 81 
patients who experience infrequent (< 2) or frequent (≥ 2) severe asthma exacerbations in the 82 
following 48 weeks 83 
 84 
  Marker * Logistic Regression 
 Constant Coefficient Model P 
value 
AUC  
N
=
1
4
2
 (
2
4
/1
4
2
, 
1
6
.9
%
 f
re
q
u
e
n
t 
se
v
e
re
) 
Individual      
 ALPL -0.4141298 -0.1112192 0.0210 0.6780 
P=0.002 
 CLC 1.133079 -0.2618302 0.0004 0.7444 
P<0.0001 
 CPA3 1.799899 -0.3078733 0.0002 0.7429 
P<0.0001 
 CXCR2 -0.8829863 -0.0442772 0.0323 0.6480 
P=0.016 
 DNASE1L3 2.309992 -0.2999175 0.0021 0.7270 
P<0.0001 
 IL1B -0.9561744 -0.0529377 0.0320 0.6448 
P=0.013 
Combination      
6GS ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
1.653505 -0.0366669 
-0.1419366 
-0.2420405 
0.0328808 
0.0800461 
-0.0380849 
0.0091 0.7613 
P<0.0001 
*Markers are normalized to beta-actin mRNA expression (∆CT)  85 
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Supplemental Table E3. Analysis of prognostic value of the sputum 6GS for discriminating 86 
patients who experience none or some total (moderate and severe) asthma exacerbations in the 87 
following 48 weeks 88 
  Marker * Logistic Regression 
 Constant Coefficient Model P 
value 
AUC  
N
=
1
4
2
 (
8
4
/1
4
2
, 
5
9
.2
%
 t
o
ta
l 
e
x
a
ce
rb
a
to
rs
) 
Individual      
 ALPL 2.021271 -0.1683247 0.0014 0.6741 
P<0.0001 
 CLC 1.116 -0.0229152 0.0096 0.6332 
P=0.006 
 CPA3 0.9125818 -0.00059   0.0102 0.6172 
P=0.016 
 CXCR2 0.9289623 -0.0041664 0.0102 0.6361 
P=0.004 
 DNASE1L3 0.5852789 0.0276092   0.0098 0.6404 
P=0.003 
 IL1B 0.9864461 -0.0257423 0.0099 0.6381 
P=0.003 
Combination      
6GS ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
0.9350901 -0.4127687 
-00.0361907 
-.0101578 
0.2094708 
0.1425817 
0.1086857 
0.0115 0.7114 
P<0.0001 
*Markers are normalized to beta-actin mRNA expression (∆CT)  89 
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Supplemental Table E4. Analysis of diagnostic value of the sputum 6GS for discriminating 90 
patients who experience infrequent or frequent total (moderate and severe) asthma 91 
exacerbations in the following 48 weeks 92 
  Marker * Logistic Regression 
 Constant Coefficient Model P 
value 
AUC  
N
=
1
4
2
 (
5
6
/1
4
2
, 
3
9
.4
%
 f
re
q
u
e
n
t 
to
ta
l 
e
x
a
ce
rb
a
to
rs
) 
Individual      
 ALPL .7881897 -0.1265727 0.0148 0.6433 
P=0.004 
 CLC 1.152437 -0.1299279 0.0060 0.6555 
P=0.002 
 CPA3 1.413362 -0.1452072 0.0054 0.6530 
P=0.002 
 CXCR2 0.3325545 -0.0675409 0.0332 0.6219 
P=0.015 
 DNASE1L3 1.606988 -0.1402179 0.0145 0.6453 
P=0.003 
 IL1B 0.2776118 -0.0991223 0.0264 0.6292 
P=0.007 
Combination      
6GS ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
1.462895 -0.0890073 
-0.068176 
-0.1237933 
0.039212 
0.074877 
-0.0496472 
0.0876 0.6649 
P=0.001 
*Markers are normalized to beta-actin mRNA expression (∆CT)  93 
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Supplemental Table E5. AUC for each predictive marker by study population, exacerbation 94 
severity and exacerbation frequency status.  95 
   6GS Sputum 
eosinophils 
Sputum 
neutrophils 
PBE 6GS  
(FENO)
 Ω
 
FENO 
P
la
ce
b
o
 T
o
ta
l 
e
xa
ce
rb
a
ti
o
n
s 
 
≥ 
1
 o
r 
0
 AUC=0.711 
P=0.003 
N=73 
 
AUC=0.505 
P=0.947 
N=73 
 
AUC=0.582 
P=0.263 
N=73 
 
AUC=0.602 
P=0.165 
N=73 
 
 
AUC=0.738 
P=0.026 
N=34 
AUC=480 
P=0.846 
N=34 
≥ 
2
 o
r 
0
-1
 AUC=0.706 
P=0.001 
N=73 
 
AUC=0.575 
P=0.269 
N=73 
 
AUC=0.554 
P=0.428 
N=73 
 
 
AUC=0.606 
P=0.110 
N=73 
 
AUC=0.561 
P=0.576 
N=34 
AUC=0.550 
P=0.627 
N=34 
S
e
v
e
re
 e
xa
ce
rb
a
ti
o
n
s 
 
≥ 
1
 o
r 
0
 AUC=0.676 
P=0.005 
N=73 
 
AUC=0.547 
P=0.499 
N=73 
 
 
AUC=0.593 
P=0.181 
N=73 
 
AUC=0.558 
P=0.397 
N=73 
 
AUC=0.712 
P=0.020 
N=34 
AUC=0.535 
P=0.741 
N=34 
≥ 
2
 o
r 
0
-1
 AUC=0.776 
P<0.0001 
N=73 
 
AUC=0.701 
P=0.004 
N=73 
 
AUC=0.563* 
P=0.436 
N=73 
 
AUC=0.628 
P=0.091 
N=73 
 
AUC=0.810 
P<0.0001 
N=34 
AUC=0.634 
P=0.213 
N=34 
A
Z
M
 T
o
ta
l 
e
xa
ce
rb
a
ti
o
n
s 
 
≥ 
1
 o
r 
0
 
AUC=0.643 
P=0.038 
N=66 
AUC=0.544 
p=0.540 
N=66 
AUC=0.479  
p=0.776 
N=66 
AUC=0.524  
p=0.740 
N=66 
AUC=0. 640 
p=0.160 
N=33 
 
AUC=0.529  
p=0.783 
N=33 
 
≥ 
2
 o
r 
0
-1
 AUC=0.610 
P=0.150 
N=66 
AUC=0.431 
P=0.386 
N=66 
AUC=0.470 
P=0.698 
N=66 
AUC=0.511 
P=0.891 
N=66 
AUC=0.609 
P=0.348 
N=33 
 
AUC=0.565 
P=0.536 
N=33 
 
S
e
v
e
re
 e
xa
ce
rb
a
ti
o
n
s 
 
≥ 
1
 o
r 
0
 AUC=0.741 
P<0.0001 
N=66 
AUC=0.534* 
P=0.669 
N=66 
AUC=0.469 
¥ 
P=0.675 
N=66 
AUC=0.592 
P=0.229 
 
AUC=0.804 
P<0.0001 
N=33 
 
AUC=0.583 
§
 
P=0.444 
N=33 
 
≥ 
2
 o
r 
0
-1
 AUC=0.750 
P=0.013 
N=66 
AUC=0.467* 
P=0.807 
N=66 
AUC=0.293 
¥
 
P=0.055 
N=66 
AUC=0.678 
P=0.081 
N=66 
AUC=0.767 
P=0.125 
N=33 
 
AUC=0.600 
P=0.394 
N=33 
 
Ω
values calculated in subpopulation where FENO measurement was made, *p<0.05 vs 6GS; 
¥
p<0.01 vs 6GS; 96 
§
p<0.01 vs 6GS (FENO subpopulation)  97 
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Supplemental Table E6. Analysis of prognostic value of the sputum 6GS for discriminating 98 
patients who experience none or some severe asthma exacerbations in following 48 weeks  99 
  Marker * Logistic Regression 
 Constant Coefficient Model P 
value 
AUC 
(95%CI) 
P
la
ce
b
o
 g
ro
u
p
. 
N
=
7
3
 (
2
9
/7
3
, 
3
9
.7
%
 s
e
v
e
re
 e
x
a
ce
rb
a
to
rs
) Individual      
 ALPL 1.174711 -0.2524459 0.0335 0.6552, 
p=0.017 
 CLC 1.311412 -0.1935234 0.0293 0.6481, 
p=0.021 
 CPA3 1.121902 -0.1565537 0.1088 0.5862, 
p=0.204 
 CXCR2 0.0996914 -0.0977394 0.3993 0.5846, 
p=0.217 
 DNASE1L3 2.178457 -0.2240271 0.1038 0.6042, 
p=0.122 
 IL1B 0.1822344 -0.1986743 0.1491 0.5799, 
p=0.259 
Combination      
6GS ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
2.553787 -0.2441983 
-0.1503987 
-0.0236053 
0.0817315 
-0.0199114 
-0.0210936 
0.2311 0.6763 
P=0.005 
A
Z
M
 g
ro
u
p
. 
N
=
6
9
 (
2
2
/6
9
, 
3
1
.9
%
 s
e
v
e
re
 e
x
a
ce
rb
a
to
rs
) 
Individual      
 ALPL -0.2789161 -0.0735923 0.5923 0.5184, 
p=0.813 
 CLC 0.7462753 -0.1546867 0.1193 0.5841 
p=0.244 
 CPA3 1.087588 -0.182063 0.0805 0.6190, 
p=0.088 
 CXCR2 -1.351341 0.1113008 0.4124 0.5754, 
p=0.346 
 DNASE1L3 0.2451273 -0.0881535 0.4917 0.5368, 
p=0.622 
 IL1B -0.7417235 -0.0056191 0.9669 0.5029, 
p=0.971 
Combination      
6GS ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
-0.2663717 -0.5786811 
-0.0886016 
-0.3606021 
0.6540632 
0.4044179 
-0.0915628 
0.0966 0.7447 
P<0.0001 
*Markers are normalized to beta-actin mRNA expression (∆CT) 100 
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Supplemental Table E7. Analysis of diagnostic value of the sputum 6GS for discriminating 101 
patients who experience infrequent (< 2) or frequent (≥ 2) severe asthma exacerbations in 102 
following 48 weeks 103 
  Marker * Logistic Regression 
 Constant Coefficient Model P 
value 
AUC 
(95%CI) 
P
la
ce
b
o
 g
ro
u
p
. 
N
=
7
3
 (
x
1
8
/7
3
, 
2
4
.7
%
 f
re
q
u
e
n
t 
se
v
e
re
) 
Individual      
 ALPL -0.665708 -0.0708267 0.5671 0.5747, 
p=0.342 
 CLC   1.79629 -0.3441432 0.0017 0.7434, 
p<0.0001 
 CPA3 2.70536 -0.4086174 0.0009 0.7354, 
p<0.0001 
 CXCR2 -0.879162 -0.0450079 0.7307 0.5242, 
p=0.753 
 DNASE1L3 2.292987 -0.2984015 0.0615 0.6525, 
p=0.039 
 IL1B -1.010963 -0.0347323 0.8202 0.4828, 
p=0.844 
Combination      
6GS ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
1.910656 0.000224 
-0.2322196 
-0.4001086 
-0.0767063 
0.2721843 
-0.0170972 
0.0305 0.7758   
P<0.0001 
A
Z
M
 g
ro
u
p
. 
N
=
6
9
 (
6
/6
9
, 
8
.7
%
 f
re
q
u
e
n
t 
se
v
e
re
) 
Individual      
 ALPL -0.8723939 -0.2375642 0.2961 0.5714 
P=0.571 
 CLC -1.152898 -0.1256578 0.4212 0.5132 
P=0.907 
 CPA3   -0.78702 -0.1579249 0.3320 0.6032 
P=0.329 
 CXCR2 -2.132548 -0.0422384 0.8482 0.4815 
P=0.907 
 DNASE1L3 0.9566618 -0.3022422 0.1425 0.6534 
P=0.111 
 IL1B -2.078326 -0.0922804 0.6817 0.5661 
P=0.531 
Combination      
6GS ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
2.057035 -0.6730842 
0.0791463 
0.2137911 
0.6367583 
-0.5728786 
-0.0484114 
0.5772 0.7540 
P=0.009 
*Markers are normalized to beta-actin mRNA expression (∆CT) 104 
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Supplemental Table E8. Analysis of prognostic value of the sputum 6GS for discriminating 105 
patients who experience none or some total (moderate and severe) asthma exacerbations in 106 
following 48 weeks 107 
  Marker * Logistic Regression 
 Constant Coefficient Model P 
value 
AUC 
(95%CI) 
P
la
ce
b
o
 g
ro
u
p
. 
N
=
7
3
 (
5
2
/7
3
, 
7
1
.2
%
 t
o
ta
l 
e
x
a
ce
rb
a
to
rs
) Individual      
 ALPL 2.744964 -0.2750237 0.0184 0.6896, 
p=0.015 
 CLC 1.044878 -0.0151497 0.8676 0.5238 
P=0.776 
 CPA3 0.9904325 -0.0084182 0.9344 0.4707   
P=0.703 
 CXCR2 1.54365 -0.1171154 0.3326 0.6200 
P=0.125 
 DNASE1L3 0.9053008 0.0001218 0.9993 0.5156 
p=0.847 
 IL1B 1.433011 -0.1650851 0.2606 0.5925 
P=0.222 
Combination      
6GS ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
1.82736 -0.3766049 
0.0077007 
-0.0338994 
-0.0014933 
0.123925 
0.1294379 
0.3862 0.7106 
P=0.003 
A
Z
M
 g
ro
u
p
. 
N
=
6
9
 (
3
2
/6
9
, 
4
6
.4
%
 t
o
ta
l 
e
x
a
ce
rb
a
to
rs
) 
Individual      
 ALPL 0.1277557 -0.041565 0.7463 0.5025 
p=0.972 
 CLC 0.1613086 -0.0309722 0.7376 0.4975 
p=0.971 
 CPA3 -0.2102336 0.0062969 0.9476 0.5194 
p=0.785 
 CXCR2 -0.7677189 0.1182769 0.3501 0.5794 
P=0.259 
 DNASE1L3 -0.6843071 0.0470349 0.6959 0.5346   
P=0.627 
 IL1B -0.3903965 0.0789144 0.5345 0.5456 
P=0.521 
Combination      
6GS ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
-0.5183495 -0.6414888 
-0.0522411 
0.0004421 
0.5629461 
0.1618661 
0.0880836 
0.3576 0.6816 
P=0.005 
*Markers are normalized to beta-actin mRNA expression (∆CT)  108 
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Supplemental Table E9. Analysis of diagnostic value of the sputum 6GS for discriminating 109 
patients who experience infrequent or frequent total (moderate and severe) asthma 110 
exacerbations in following 48 weeks 111 
  Marker * Logistic Regression 
 Constant Coefficient Model P 
value 
AUC 
(95%CI) 
P
la
ce
b
o
. 
N
=
7
3
 (
3
6
/7
3
, 
4
9
.3
%
 f
re
q
u
e
n
t 
to
ta
l 
e
x
a
ce
rb
a
to
rs
) 
Individual      
 ALPL 1.37584 -0.2187011 0.0495 0.6569 
P=0.018 
 CLC 2.287965 -0.255561 0.0042 0.6959 
P=0.002 
 CPA3 2.55715 -0.2607424 0.0089 0.6569 
P=0.015 
 CXCR2 0.9757104 -0.1889486 0.1021 0.6081 
P=0.112 
 DNASE1L3 3.415742 -0.2956417 0.0316 0.6404 
P=0.033 
 IL1B 0.4134511 -0.1433317 0.2820 0.5548 
P=0.425 
Combination      
6GS ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
3.8649 -0.1726814 
-0.1481676 
-0.1704555 
-0.1120212 
0.0449441 
0.0985971 
0.0640 0.7057 
P=0.001 
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) 
Individual      
 ALPL -0.9968258 0.0153026 0.9137 0.5378 
p=0.635 
 CLC -1.157131 0.026261 0.7973 0.5633 
P=0.395 
 CPA3 -0.6788128 -0.0210921 0.8409 0.4796 
P=0.784 
 CXCR2 -1.463457 0.1064686 0.4452 0.5704 
P=0.379 
 DNASE1L3 -0.8950519 0.0000905 0.9995 0.4765 
P=0.762 
 IL1B -0.7406066 -0.0508403 0.7153 0.5378 
0.625 
Combination      
6GS ALPL 
CLC 
CPA3 
CXCR2 
DNASE1L3 
IL1B 
-0.9970808 -0.2584836 
0.0914051 
-0.0990941 
0.4106918 
0.0193966 
-0.1623113 
0.8283 0.6265 
P=0.097 
*Markers are normalized to beta-actin mRNA expression (∆CT)  112 
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Supplemental Table E10. Comparison of diagnostic value of sputum 6GS vs PBE & FENO for 113 
asthma airway inflammatory phenotyping 114 
 115 
Phenotype  6-Gene Signature PBE P value  
6GS vs PBE 
EA vs NEA 
N=139 
AUC=0.7684 
P<0.0001 
AUC=0.7591 
P<0.0001 
0.858 
EA vs NA 
N=79 
AUC= 0.9294 
P<0.0001 
AUC= 0.7159 
P=0.001 
0.002 
EA vs PGA 
N=118 
AUC=0.7636 
P<0.0001 
AUC= 0.7726 
P<0.0001 
0.873 
    
Phenotype   6-Gene Signature FENO P value  
6GS vs FENO 
EA vs NEA 
N=67 
AUC=0.8152 
P<0.0001 
AUC=0.7268 
P<0.0001 
0.242 
EA vs NA 
N=41 
AUC= 0.9569 
P<0.0001 
AUC= 0.7615 
P=0.001 
0.015 
EA vs PGA 
N=55 
AUC=0.8383 
P<0.0001 
AUC= 0.7147 
P=0.003 
0.136 
 116 
 117 
  118 
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